- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Advanced practice nursing.
Displaying page 1 of 1.
| EudraCT Number: 2014-004552-64 | Sponsor Protocol Number: 131016 | Start Date*: 2017-07-03 |
| Sponsor Name:Center for Digestive Diseases, Karolinska University Hospital | ||
| Full Title: MISTRAL - Mistletoe therapy in primary and recurrent inoperable pancreatic cancer - A phase III prospective, randomized, double blinded, multicenter, parallel group, placebo controlled clinical tr... | ||
| Medical condition: Primary or recurrent inoperable pancreatic cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-004117-24 | Sponsor Protocol Number: GETUG-AFU26 | Start Date*: 2015-12-24 | |||||||||||
| Sponsor Name:UNICANCER | |||||||||||||
| Full Title: A Phase II Safety Trial of Nivolumab in Patients with Metastatic Renal Cell Carcinoma Who Have Progressed During or After Prior Systemic Anti-Angiogenic Regimen | |||||||||||||
| Medical condition: Patients suffering from refractory metastatic Renal Cell Carcinoma. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-000817-20 | Sponsor Protocol Number: 6002-EU-007 | Start Date*: 2004-10-22 |
| Sponsor Name:Kyowa Hakko U.K. Limited | ||
| Full Title: A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entac... | ||
| Medical condition: Parkinson's Disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: LV (Completed) AT (Completed) LT (Completed) GB (Completed) IT (Completed) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-002260-14 | Sponsor Protocol Number: UC-0105/1612 | Start Date*: 2017-04-03 |
| Sponsor Name:UNICANCER | ||
| Full Title: Secured access to pembrolizumab for adult patients with selected rare cancer types. | ||
| Medical condition: Patients with unresectable locally advanced or metastatic, rare soft tissue sarcoma, visceral sarcoma, or bone sarcoma, rare ovarian cancer, primary central nervous system lymphomas (PCNSL), rare t... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-002257-37 | Sponsor Protocol Number: UC-0105/1611 | Start Date*: 2017-02-10 |
| Sponsor Name:UNICANCER | ||
| Full Title: Secured access to nivolumab for adult patients with selected rare cancer types | ||
| Medical condition: Unresectable locally advanced or metastatic, non-clear cell renal cell carcinoma, rare head and neck cancer, rare skin cancer, MSI-nonCRC or penile cancer, which is resistant or refractory to stand... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-002093-12 | Sponsor Protocol Number: 1506-STBSG | Start Date*: 2017-07-04 | ||||||||||||||||
| Sponsor Name:European Organisation for Research and Treatment of | ||||||||||||||||||
| Full Title: A Phase II multicenter study comparing the efficacy of the oral angionenesis inhibitor nintedanib with the intravenous cytotoxis compound ifosfamide for treatment of patients with advanced metastat... | ||||||||||||||||||
| Medical condition: Metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) NL (Completed) ES (Completed) LT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2018-000053-53 | Sponsor Protocol Number: EORTC-1714-ROG-GITCG | Start Date*: 2018-11-15 | ||||||||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer | ||||||||||||||||||
| Full Title: Phase II trial in inoperable œsophageal cancer evaluating the feasibility of the combination of definitive chemoradiation with the immune checkpoint blockers Nivolumab +/- Ipilimumab (CRUCIAL) | ||||||||||||||||||
| Medical condition: oesophageal squamous cell carcinoma and oeasophageal adenocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-000149-15 | Sponsor Protocol Number: NEEDS | Start Date*: 2020-04-22 | ||||||||||||||||
| Sponsor Name:Karolinska University Hospital | ||||||||||||||||||
| Full Title: NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial). | ||||||||||||||||||
| Medical condition: Resectable locally advanced squamous cell carcinoma (SCC) of the esophagus | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-000086-74 | Sponsor Protocol Number: 1559-HNCG | Start Date*: 2017-10-05 | |||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
| Full Title: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck "UPSTREAM" | |||||||||||||
| Medical condition: Recurrent/metastatic squamous cell carcinoma of the head and neck | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-001225-33 | Sponsor Protocol Number: UC-0105/1401 | Start Date*: 2014-07-21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patient with BRAF V600 mutation determined on the primary and/or metastatic lesion in the following pathologies: . NSCLC . Ovarian cancer . Cholangiocarcinoma . Thyroid cancer . Prostatic canc... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-000885-13 | Sponsor Protocol Number: UC-0105/1303 | Start Date*: 2013-07-31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with metastatic or unresectable locally advanced malignancies harboring specific genomic alterations regarding the biological crizotinib targets, and who are no more amenable to curative t... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
